BrainsWay Ltd. (NASDAQ:BWAY) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in BrainsWay Ltd. (NASDAQ:BWAY) by 61.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,918 shares of the company’s stock after acquiring an additional 9,149 shares during the quarter. JPMorgan Chase & Co. owned 0.13% of BrainsWay worth $226,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Rhumbline Advisers grew its position in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the period. ARK Investment Management LLC purchased a new stake in shares of BrainsWay in the fourth quarter worth about $1,656,000. Finally, Sei Investments Co. purchased a new stake in shares of BrainsWay in the fourth quarter worth about $149,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Stock Performance

BWAY opened at $9.02 on Friday. The company has a fifty day moving average of $9.18 and a two-hundred day moving average of $9.75. The stock has a market capitalization of $170.20 million, a price-to-earnings ratio of 90.21 and a beta of 1.25. BrainsWay Ltd. has a fifty-two week low of $5.13 and a fifty-two week high of $11.79.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a report on Wednesday, March 12th.

BrainsWay Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.